Danahervs.Illumina
DHR vs ILMN · both in Life science tools, part of the Medicine, pharma & life science value chain: Instruments, reagents and equipment for research, development and production.
Danaher is about 5.0× larger than Illumina by market cap; year to date, Illumina leads (+70.2% vs −6.0%).
Side by side
| DHR | ILMN | |
|---|---|---|
| Market cap | $144B | $28.7B |
| Price | $215.97 | $224.99 |
| Today | +0.4% | +0.8% |
| Return YTD | −6.0% | +70.2% |
| Return 1Y | +1.6% | +119.3% |
| P/E | 35.9 | 34.7 |
| P/S | 5.7 | 6.4 |
| P/B | 2.7 | 10.1 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
DanaherDHR
Cytiva supplies the equipment biologics are made with; Cepheid runs molecular diagnostics. Danaher owns both, along with a wider set of life science instruments.
Full DHR profile →IlluminaILMN
DNA sequencing machines and the reagents they consume, for research and clinical genomics.
Full ILMN profile →More DHR & ILMN comparisons
Other head-to-heads in the Life science tools segment.
See where DHR and ILMN sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →